相关实验视频
Updated: May 3, 2026

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 25, 2010
17.6K
多模式技术用于阿尔茨海默病的诊断和预后
Richard J Perrin1, Anne M Fagan, David M Holtzman
1Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.
Nature
|October 16, 2009
概括
阿尔茨海默氏症涉及到在痴呆症发生前几年的脑蛋白错折. 新的成像和生物标记技术可能能够对这种神经退行性疾病进行早期检测和干预.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一个全球性的健康挑战,影响着数百万人.
- 阿尔茨海默病的特征是蛋白质错误折叠和随后的脑损伤,先于痴呆的发病.
- 目前的治疗方法无法预防或减缓阿尔茨海默病的进展.
研究的目的:
- 为突出阿尔茨海默病病理学的临床前检测方面的进展.
- 强调早期,基于机制的治疗干预的潜力.
- 为未来阿尔茨海默病临床试验的设计提供信息.
主要方法:
- 使用新的神经成像技术.
- 使用先进的液体生物标记分析.
- 研究阿尔茨海默病的临床前阶段.
主要成果:
- 阿尔茨海默病的病理在临床前阶段是可以检测到的.
- 新的诊断工具显示了早期AD识别的希望.
- 早期发现有助于及时制定治疗策略.
结论:
- 神经成像和生物标志物的进步使得阿尔茨海默病的临床前检测成为可能.
- 早期识别为基于机制的治疗开辟了道路.
- 这些进展对于设计有效的阿尔茨海默氏症临床试验至关重要.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

